scholarly journals 1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome

2021 ◽  
Vol 32 ◽  
pp. S962-S963
Author(s):  
M. Nishio ◽  
L. Paz-Ares ◽  
M. Reck ◽  
K. Nakagawa ◽  
E.B. Garon ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Egfr Mutant ◽  
Tp53 Status

scholarly journals Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0207001 ◽  
Author(s):  
Kang-Yi Su ◽  
Jeng-Sen Tseng ◽  
Keng-Mao Liao ◽  
Tsung-Ying Yang ◽  
Kun-Chieh Chen ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Lung Adenocarcinoma ◽  
Outcome Prediction ◽  
Clinical Outcome Prediction ◽  
Egfr Mutant ◽  
Egfr T790m

Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 8072-8072
Author(s):  
Niki Karachaliou ◽  
Ana Drozdowskyj ◽  
Ana Gimenez Capitan ◽  
Andres Felipe Cardona Zorrilla ◽  
Radj Gervais ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Outcome ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutant ◽  
Nsclc Patients

BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e19078-e19078
Author(s):  
Rosario Garcia Campelo ◽  
Teresa Moran ◽  
Felipe Cardenal ◽  
Guillermo Alonso-Jaudenes Curbera ◽  
Enric Carcereny Costa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Outcome ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Egfr Mutant ◽  
Nsclc Patients

10 years clinical outcome of TKIs in EGFR-mutant advanced NSCLC – UHNM experience

Lung Cancer ◽  
2021 ◽  
Vol 156 ◽  
pp. S33-S34
Author(s):  
Abdelfattah Elmasry ◽  
Nillegoda Hasanthi ◽  
Selvaraj Giridharan ◽  
Salil Vengalil ◽  
Apurna Jegannathen
Keyword(s):  
Clinical Outcome ◽  
Advanced Nsclc ◽  
Egfr Mutant

Assessing TP53 status in human tumours to evaluate clinical outcome

2001 ◽  
Vol 1 (3) ◽  
pp. 233-239 ◽  
Author(s):  
Thierry Soussi ◽  
Christophe Béroud
Keyword(s):  
Clinical Outcome ◽  
Human Tumours ◽  
Tp53 Status

scholarly journals Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors

2019 ◽  
Vol 12 (11) ◽  
pp. 1425-1431 ◽  
Author(s):  
Shih-Chieh Chang ◽  
Yi-Chun Lai ◽  
Cheng-Yu Chang ◽  
Li-Kuo Huang ◽  
Shu-Jen Chen ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Genetic Alterations ◽  
Egfr Mutant ◽  
Nsclc Patients

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?

2014 ◽  
Vol 73 (5) ◽  
pp. 1063-1070 ◽  
Author(s):  
Ji Yun Lee ◽  
Sung Hee Lim ◽  
Moonjin Kim ◽  
Sungmin Kim ◽  
Hyun Ae Jung ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Egfr Mutant ◽  
Nsclc Patients ◽  
Egfr Tkis

Clinical outcome and long-term survival following radical esophagectomy in the elderly

2001 ◽  
Vol 120 (5) ◽  
pp. A747-A748
Author(s):  
S DRESNER ◽  
A IMMMANUEL ◽  
P LAMB ◽  
S GRIFFIN
Keyword(s):  
Clinical Outcome ◽  
The Elderly ◽  
Radical Esophagectomy ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document